Dr. Doherty (Jim) is President and Chief Development Officer at Acumen Pharmaceuticals and brings over two decades of leadership experience in CNS R&D, including the development of novel medicines, such as Zulresso and Zurzuvae. Before joining Acumen, he was Chief Development Officer at Sage Therapeutics, where he led the development of novel medicines to treat CNS disorders. Dr Doherty held multiple roles during his tenure at Sage, leading efforts at various times in Preclinical Research, Experimental Medicine, and Clinical Development. Jim has led multiple program teams to progress candidate molecules through the stages of drug discovery and development. His experience with company-building, collaboration management, investor relations, and regulatory interactions has helped to build significant value to CNS pipelines.
Before Sage, Dr. Doherty was head of the preclinical Neuroscience department for the CNS and Pain Innovative Medicine unit of AstraZeneca Pharmaceuticals, where he was responsible for leading preclinical neuroscience research and advanced over 20 programs into clinical development. He has extensive experience leading programs in neurology, psychiatry, analgesia, seizure control, and cognition.
Dr. Doherty has published over 250 peer-reviewed scientific papers, abstracts, and conference presentations, and holds multiple patents. He received his B.A. from the University of Delaware, Ph.D. from Georgetown University and completed a postdoctoral fellowship at Emory University School of Medicine.
What is James J. Doherty's net worth?
The estimated net worth of James J. Doherty is at least $135.52 thousand as of January 7th, 2026. Dr. Doherty owns 60,500 shares of Acumen Pharmaceuticals stock worth more than $135,520 as of August 5th. This net worth estimate does not reflect any other assets that Dr. Doherty may own. Learn More about James J. Doherty's net worth.
How do I contact James J. Doherty?
Has James J. Doherty been buying or selling shares of Acumen Pharmaceuticals?
James J. Doherty has not been actively trading shares of Acumen Pharmaceuticals over the course of the past ninety days. Most recently, James J. Doherty sold 6,467 shares of the business's stock in a transaction on Thursday, January 8th. The shares were sold at an average price of $1.82, for a transaction totalling $11,769.94. Following the completion of the sale, the insider now directly owns 54,033 shares of the company's stock, valued at $98,340.06. Learn More on James J. Doherty's trading history.
Who are Acumen Pharmaceuticals' active insiders?
Are insiders buying or selling shares of Acumen Pharmaceuticals?
During the last year, insiders at the sold shares 30 times. They sold a total of 188,518 shares worth more than $374,717.53. The most recent insider tranaction occured on June, 17th when Director Derrell Porter sold 13,040 shares worth more than $30,383.20. Insiders at Acumen Pharmaceuticals own 10.2% of the company.
Learn More about insider trades at Acumen Pharmaceuticals. Information on this page was last updated on 6/17/2026.
